Lisa Padilla, JD, LLM
CEO & CO-FOUNDER
Business/Tax Attorney, Angel Investor, Boston University, BS, LLM; Suffolk University, JD; Callen Lorde Community Health Center Board Member 2014 – Present (Audit, Finance and By-Laws Committees).
Dr. Alison Lukacsko
CSO & CO-FOUNDER
VP, GM and VP of Innovation, Research & Development, Georgia-Pacific, LLC; VP Business Development & R&D, Church & Dwight; Sr. Director and R&D Director Bristol-Myers Squibb (including women’s health).
Allison Drew Klein
Pitney Bowes (30+ years, sales), Angel Investor.
MANAGEMENT TEAM & CO-FOUNDERS
The Beryl team brings passion, experience and knowledge to the development of treatments for bone disease. The company is harnessing the synergy of strong internal management, best in class advisors and leading contract research organizations.
Professor, Dept. of Medicine and former Chair of the Dept. of Oral Medicine, Infection, and Immunity, Harvard University. Dr. Baron has been involved in bone biology research for over 35 years and applies knowledge of the pathophysiology of skeletal diseases to developing new therapeutic approaches for bone disorders. Dr. Baron has extensive experience in the characterization of mouse models, with over 370 scientific papers in the field of bone biology and bone diseases. He has held leadership positions in industry, including Vice President and Head of Bone Diseases Research at Aventis (now Sanofi), as well as CSO and Head of R&D at Proskelia, a small pharmaceutical company he founded devoted to the discovery and development of new drugs for bone and hormonal dependent diseases.
Director, Center for Advanced Orthopaedic Studies, Beth Israel Deaconess Medical Center. Professor, Department of Orthopedic Surgery, Harvard Medical School; Associate Biologist, Endocrine Division, Massachusetts General Hospital; Adjunct Assistant Professor, Department of Mechanical Engineering, Boston University; Faculty Member, Bioastronautics Program, Harvard-MIT Division of Health Sciences and Technology.
DVM, PhD, DACVP
Executive director, Amgen 2009-2017; Manager of Pathology Laboratory (Thousand Oaks); Nonclinical safety lead, denosumab and romosozumab; participated in writing of denosumab BLA and participation in advisory committee meetings; lead for nonclinical modules for romosozumab BLA and regulatory interactions.
Clinical scientist, osteoporosis specialist, endocrinologist, Prof. of Medicine Columbia University Medical School, & North American
Co-Editor in Chief of Osteoporosis International. She investigated cyclic, combination & sequential regimens of teriparatide and antiresorptive agents; evaluated teriparatide’s effect on bone formation (human femur); lead contributor to pivotal studies of abaloparatide and romosozumab.
Javier San Martin
Former lead clinical development in bone, osteoporosis (Lilly, Amgen) and in rare diseases former lead for the development of FGF23 antibodies for XLH at Ultragenyx.
Director of Research, Bone Laboratory at the Sackler Faculty of Medicine, Tel Aviv University. He is the co-author of one of Beryl's scientific publications on Prader-Willi Syndrome.
SAB Chair, Associate Dean for Research; Professor; Director, Neuroscience Research Center at Medical College of Wisconsin.
MS, DACVS, ACVS Founding Fellow, Surgical Oncology, Director of the Columbine Health Systems Center for Healthy Aging.
Entrepreneur & Biotechnology leader at TeOno Perspectives; former Head of Nestle Institute of Health Sciences, VP of research & development of DFB Pharmaceuticals.
Entrepreneur, Scientific Advisor and Biotechnology Leader; CEO AvaChrome Inc. and former Director and Scientific Founder of the Nestle Institute of Health Sciences. Creator of science-driven companies and institutions for translational purposes. Areas of expertise include: cell therapy, endocrinology, metabolism, neurobiology, nutrition, regenerative medicine, omics and digital technologies.
Former Senior Director Flavor Development & Materials, PepsiCo Global Beverages, and a Master Flavorist with 25+ years of experience in product develop-ment and three patents granted in the food and beverage space.